tetano
Editor, Senior Moderator
Mayo Clin Proc
. 2020 Sep;95(9):1989-1999.
doi: 10.1016/j.mayocp.2020.06.018. Epub 2020 Jul 19.
Targeting TMPRSS2 in SARS-CoV-2 Infection
Linda B Baughn[SUP] 1 [/SUP], Neeraj Sharma[SUP] 1 [/SUP], Eran Elhaik[SUP] 2 [/SUP], Aleksandar Sekulic[SUP] 3 [/SUP], Alan H Bryce[SUP] 4 [/SUP], Rafael Fonseca[SUP] 5 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has rapidly caused a global pandemic associated with a novel respiratory infection: coronavirus disease-19 (COVID-19). Angiotensin-converting enzyme-2 (ACE2) is necessary to facilitate SARS-CoV-2 infection, but-owing to its essential metabolic roles-it may be difficult to target it in therapies. Transmembrane protease serine 2 (TMPRSS2), which interacts with ACE2, may be a better candidate for targeted therapies. Using publicly available expression data, we show that both ACE2 and TMPRSS2 are expressed in many host tissues, including lung. The highest expression of ACE2 is found in the testes, whereas the prostate displays the highest expression of TMPRSS2. Given the increased severity of disease among older men with SARS-CoV-2 infection, we address the potential roles of ACE2 and TMPRSS2 in their contribution to the sex differences in severity of disease. We show that expression levels of ACE2 and TMPRSS2 are overall comparable between men and women in multiple tissues, suggesting that differences in the expression levels of TMPRSS2 and ACE2 in the lung and other non-sex-specific tissues may not explain the gender disparities in severity of SARS CoV-2. However, given their instrumental roles for SARS-CoV-2 infection and their pleiotropic expression, targeting the activity and expression levels of TMPRSS2 is a rational approach to treat COVID-19.
. 2020 Sep;95(9):1989-1999.
doi: 10.1016/j.mayocp.2020.06.018. Epub 2020 Jul 19.
Targeting TMPRSS2 in SARS-CoV-2 Infection
Linda B Baughn[SUP] 1 [/SUP], Neeraj Sharma[SUP] 1 [/SUP], Eran Elhaik[SUP] 2 [/SUP], Aleksandar Sekulic[SUP] 3 [/SUP], Alan H Bryce[SUP] 4 [/SUP], Rafael Fonseca[SUP] 5 [/SUP]
Affiliations
- PMID: 32861340
- DOI: 10.1016/j.mayocp.2020.06.018
Abstract
Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has rapidly caused a global pandemic associated with a novel respiratory infection: coronavirus disease-19 (COVID-19). Angiotensin-converting enzyme-2 (ACE2) is necessary to facilitate SARS-CoV-2 infection, but-owing to its essential metabolic roles-it may be difficult to target it in therapies. Transmembrane protease serine 2 (TMPRSS2), which interacts with ACE2, may be a better candidate for targeted therapies. Using publicly available expression data, we show that both ACE2 and TMPRSS2 are expressed in many host tissues, including lung. The highest expression of ACE2 is found in the testes, whereas the prostate displays the highest expression of TMPRSS2. Given the increased severity of disease among older men with SARS-CoV-2 infection, we address the potential roles of ACE2 and TMPRSS2 in their contribution to the sex differences in severity of disease. We show that expression levels of ACE2 and TMPRSS2 are overall comparable between men and women in multiple tissues, suggesting that differences in the expression levels of TMPRSS2 and ACE2 in the lung and other non-sex-specific tissues may not explain the gender disparities in severity of SARS CoV-2. However, given their instrumental roles for SARS-CoV-2 infection and their pleiotropic expression, targeting the activity and expression levels of TMPRSS2 is a rational approach to treat COVID-19.